In collaboration with Natera and Lifelabs, Colorectal Cancer Canada (CCC) hosted an Information Webinar for healthcare professionals regarding the Canadian launch of Signatera™, on February 13th 2023.
Signatera™ is a highly sensitive molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA) custom designed for each patient. It will offer patients a unique and personalized diagnostic solution that can offer support for more precise clinical decisions which can be used to accurately detect and quantify residual tumour burden after treatment has started and/or completed.
Categories:
In Treatment, After Treatment
